February 24, 2020         
MAJORITY Opens First MAJORITY Meetup Location in Houston   •   TherapeuticsMD Announces Fourth Quarter and Full-Year 2019 Financial Results   •   Escape to an Animal Crossing: New Horizons Island Getaway at PAX East   •   PrideStaff Edison Owner/Strategic-Partner Named to NJBIZ 2020 Best 50 Women in Business   •   Mountain America Credit Union Donates $13,000 to St. Luke's Children's   •   PagerDuty Receives Parity.org Gateway Award for Achieving Gender Parity in Leadership Team   •   Women Mentoring Women is Taking Center Stage Today Nationwide & Impact Consulting is Part of this Significant Engagement   •   Allison Dukes to join Invesco as Deputy Chief Financial Officer; Loren Starr to become Vice Chair on Aug. 1 and retire in March   •   Café Bustelo® Will Award $100,000 in College Scholarships   •   World's Only All-Female Snowboarding Competition - Nissan Super Girl Snow Pro - Wraps Two Packed Days of Big Air & Snowboard   •   Rogers Joseph O'Donnell and ACLU Foundation of Northern California Announce Federal Judiciary Order Of Sacramento Sheriff Scott   •   Tracking Where Catholics Stand Ahead of 2020 Election   •   SCLC Hosts Democratic Presidential Candidate And Policy Forum On February 26 And 27 In Columbia, South Carolina   •   Pre-Order Starts Today with Serious Deals for EVERYONE on the Latest Samsung Galaxy S20 5G Smartphones at T-Mobile   •   P&G Launches New Line of Antibacterial Cleaning Products, Microban 24   •   The Colorado Automobile Dealers Association Launches Colorado Automotive Hall of Fame   •   MoneySKILL®, Personal Finance Course Demonstrates Effectiveness   •   Pan-American Life Insurance Group Reports Record Gains in 2019   •   Sojournix Announces Initiation of Phase 2 Clinical Trial of SJX-653, a Novel Selective NK3 Antagonist for Menopausal Hot Flashes   •   $100,000 for more mental health services for youth in the Québec City region
Bookmark and Share

Tuberous Sclerosis Alliance Lauds Lundbeck And FDA For Sabril Label Expansion For Patients 2 To 10 Years Old

Tuberous Sclerosis Alliance Lauds Lundbeck And FDA For Sabril Label Expansion For Patients 2 To 10 Years Old

PR Newswire

SILVER SPRING, Md., Jan. 27, 2020 /PRNewswire/ -- On January 24, the Tuberous Sclerosis Alliance (TS Alliance) learned the US Food and Drug Administration (FDA) formally approved Lundbeck Pharmaceutical's label expansion for Sabril® (vigabatrin) to now be available to treat refractory complex partial seizures in patients 2 to 10 years old. Previously, Sabril was only approved to treat infantile spasms in infants 1 month to 2 years of age and to treat complex partial seizures for patients 10 years and older. This new label expansion now means there will be no age gap for patients needing critical access to this medication, particularly those in the tuberous sclerosis complex (TSC) community.

TS Alliance Logo. (PRNewsFoto/Tuberous Sclerosis Alliance) (PRNewsfoto/Tuberous Sclerosis Alliance)

"Two years ago, the TS Alliance became aware insurance companies were denying coverage for vigabatrin for our community members whose children were 3 to 9 years old," said Kari Luther Rosbeck, President & CEO. "We reached out to Lundbeck to begin discussing how to address this gap utilizing, at that time, recently released global guidance for complex partial seizure medications with the ability to extrapolate efficacy information down to age 3." 

These discussions eventually resulted in the TS Alliance funding a study led by Darcy Krueger, MD, PhD, Director of the Cincinnati Children's Hospital Medical Center TSC Clinic. This study included 198 medical chart reviews by 13 TSC Clinics in the United States and concluded with a paper used as supplemental information for Lundbeck's application to the FDA for Sabril's label expansion.

"Vigabatrin has been used safely for many years to treat both infantile spasms and partial seizures, yet patients were having difficulty getting medication approved by their insurance because the previous FDA approval didn't include patients aged 2 to 10," Dr. Krueger explained. "We were able to work with TSC Clinics like ours with considerable experience treating children in this age range to collect safety and efficacy data so it could be included in the FDA's new review. We are happy to learn the FDA updated the indication so TSC patients of any age can obtain the medication when recommended by their neurologists."

An updated Sabril label can be downloaded at www.tsalliance.org/sabril-change to show insurers the broadened approved age group since the label won't be immediately available in the medication's package insert.

"This new FDA approval is a game changer for the TSC community, and we are incredibly grateful to our partners at Lundbeck who understood the need and worked diligently to obtain this label change for patients," Rosbeck said. "We are also thankful to Dr. Krueger and all the TSC Clinics who participated in the study as well as our Chief Scientific Officer Steven Roberds, PhD, who worked closely on the study."

"All of us at Lundbeck couldn't be more pleased to have secured approval for this important label change – an outcome that closes an important gap and speaks to Lundbeck's enduring commitment to doing what's right for patients," said Sally Benjamin Young, Vice President, Public Affairs at Lundbeck. "What a proud moment for us to be able to have so crucial an impact on this community."

The Tuberous Sclerosis Alliance is the only US-based nonprofit dedicated to finding a cure for tuberous sclerosis complex (TSC) while improving the lives of those affected. Founded in 1974, the organization has since become an international leader in providing support services and information, creating and implementing public and professional programs to increase awareness of the disease, and funding and driving research. For more information, visit www.tsalliance.org.

Contact:

Jaye Isham

Vice President, Communications Strategy

301-562-9890

jisham@tsalliance.org 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/tuberous-sclerosis-alliance-lauds-lundbeck-and-fda-for-sabril-label-expansion-for-patients-2-to-10-years-old-300993825.html

SOURCE Tuberous Sclerosis Alliance



Back to top
| Back to home page
Video

White House Live Stream
LIVE VIDEO EVERY SATURDAY
alsharpton Rev. Al Sharpton
9 to 11 am EST
jjackson Rev. Jesse Jackson
10 to noon CST


Video

LIVE BROADCASTS
Sounds Make the News ®
WAOK-Urban
Atlanta - WAOK-Urban
KPFA-Progressive
Berkley / San Francisco - KPFA-Progressive
WVON-Urban
Chicago - WVON-Urban
KJLH - Urban
Los Angeles - KJLH - Urban
WKDM-Mandarin Chinese
New York - WKDM-Mandarin Chinese
WADO-Spanish
New York - WADO-Spanish
WBAI - Progressive
New York - WBAI - Progressive
WOL-Urban
Washington - WOL-Urban

Listen to United Natiosns News